Sign In
Section Navigation
Common TitleStudy 130
Official Title A Phase 3b, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir Plus Two Fully Active Nucleoside Reverse Transcriptase Inhibitors in HIV-1 Infected, Antiretroviral Treatment-Naïve and -Experienced Adults With No Darunavir Resistance-associated Mutations
Phase Phase IIIB
ClinicalTrials.gov NCT01440569
Treatments
Darunavir-Cobicistat
Darunavir-Cobicistat Prezcobix

Darunavir-Cobicistat

Tradename:PrezcobixOther Names:DRV-COBIClass:Protease Inhibitors (PI)
Categories PharmacologyTreatment-NaiveTreatment-ExperiencedGeneral Pharmacology
Funding
IndustryGilead Sciences and Janssen Pharmaceuticals
References
  • Tashima K, Crofoot G, Tomaka FL, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014;11:39.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.